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Sheldon R. Morris, MD, MPH,* and Jeffrey D. Klausner, MD, MPH¶Abstract: The goal of the STAR Sexually Transmitted Infection Clinical
Trial Group (STI CTG) Programmatic meeting on Sexually Transmitted In-
fections (STIs) in Pregnancy and Reproductive Health in April 2018 was to
review the latest research and develop recommendations to improve preven-
tion and management of STIs during pregnancy. Experts from academia,
government, nonprofit, and industry discussed the burden of STIs during
pregnancy; the impact of STIs on adverse pregnancy and birth outcomes; in-
terventions that work to reduce STIs in pregnancy, and the evidence, policy,
and technology needed to improve STI care during pregnancy. Key points
of themeeting are as follows: (i) alternative treatments and therapies for use
during pregnancy are needed; (ii) further research into the relationship be-
tween the vaginal microbiome and STIs during pregnancy should be sup-
ported; (iii) more research to determine whether STI tests function
equally well in pregnant as nonpregnant women is needed; (iv) develop-
ment of new lower cost, rapid point-of-care testing assays could allow for
expanded STI screening globally; (v) policies should be implemented that
create standard screening and treatment practices globally; (vi) federal
funding should be increased for STI testing and treatment initiatives sup-
ported by the Centers for Disease Control and Prevention (CDC), the Cen-
ters of Excellence in STI Treatment, public STD clinics, and the President's
Emergency Plan for AIDS Relief (PEPFAR).From the *Division of Infectious Diseases & Global Public Health, Univer-
sity of California SanDiego School ofMedicine, SanDiego, CA; †Social
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Sciences, Division of Infectious Diseases, University of California Los
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The goal of the STAR STI CTG Programmatic meeting on
STIs in Pregnancy and Reproductive Health was to review the latest
research and develop recommendations to improve prevention and
management of STIs during pregnancy. Experts from academia,
government, nonprofit, and industry discussed the burden of STIs
during pregnancy; the impact of STIs on adverse pregnancy and
birth outcomes, interventions that work to reduce STIs in preg-
nancy; and the evidence, policy, and technology needed to im-
prove STI care during pregnancy.CURABLE STIs ARE COMMON
Sexually transmitted infections are common globally and
disproportionately affect women and pose a large public health bur-
den. In 2012, there were 6 million new cases of syphilis, 78 million
Neisseria gonorrhoeae (NG), 131 million Chlamydia trachomatis
(CT), and 143 Trichomonas vaginalis (TV) infections globally.1 A re-
cent systematic review found that the prevalence of curable STIs was
particularly high among pregnant women in low- and middle-income
countries.2 The TV prevalence was highest in Southern AfricaSOW, Mods 1-18, Solicitation). Dr. Wynn was supported by T32
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Wynn et al.(24.6%) followed by Asia (13.6%); syphilis prevalence (7.2%) was
highest in EastAfrica; NGprevalance (4.6%)was highest in Southern
Africa; and CT prevalence was very high in Latin America (11.2%).2
Untreated STIs Are Associated With Adverse
Pregnancy and Neonatal Outcomes
Curable STIs are associated with maternal morbidity,3 pre-
term birth, low birth weight, and stillbirth.4–6 Preterm birth is the
leading cause of under-five mortality globally.7 A World Health
Organization (WHO)-led study in 2013 found that prematurity
and its associated complications were the largest contributor to mor-
tality in children globally accounting for 1 million of the 6 million
under-five deaths.8 According to the March of Dimes, in the United
States, the rate of preterm birth increased to 1 in 10 babies (9.9% of
live births), and the rate is highest among black infants (13.4%).9 In
addition, there are around 2.6 million stillbirths per year of which
7% to 30% are caused by STIs or other infections.10–12
About 50% of untreated maternal CTand NG infections are
transmitted to the neonate during birth,13 which can cause eye and
lower respiratory tract infections.14 Gonococcal eye infections can
result in corneal damage and blindness if untreated.15 Pneumonia
due to CT develops in 10% to 20% of infants born to women with
untreated CT infection.16 Curable STIs are also associated with in-
creased mother-to-child transmission of HIV.17
Antenatal STIs Are Often Suboptimally Diagnosed
and Treated
Despite the large burden and risk to maternal and infant health
posed by STIs, in most countries, routine antenatal testing for CT,
NG, and TV infections is not offered.18 In 2015, only 14 countries
had policies recommending that pregnant women be tested for CT
and/or NG infections.18 In the United States (US), the CDC recom-
mends CT testing for all pregnant women and NG testing for preg-
nant women who are at increased risk or who live in areas where
NG is highly prevalent.19 Diagnostic testing for TV is recom-
mended for pregnant women seeking care for vaginal discharge
and should be considered in high-prevalence settings.19
Countries without STI testing guidelines rely on an approach
called syndromic management,20 which uses algorithms to manage
patients with specific STI syndromes (e.g., vaginal discharge syn-
drome) based on patient symptoms, clinical signs and select risk
factors.21 Patients are then treated with standardized drug regimens
for the possible causes of their syndromes, without testing for the
etiologic organism. Syndromic management has a number of bene-
fits, including timely treatment at the point-of-care, and no require-
ment for laboratory resources. Although the syndromic approach has
high sensitivity for symptomatic persons, because most STIs are
asymptomatic the approach fails to detect the large majority of preg-
nant women with infection.21,22 The syndromic approach also lacks
specificity, potentially unnecessarily exposing pregnant women to
antibiotics and undermining antimicrobial stewardship.21,22 A recent
systematic review andmeta-analysis of the performance of abnormal
vaginal discharge flowcharts used for syndromic management found
that summary diagnostic performance estimates were consistently
low for all flowcharts, regardless of whether risk assessments or clin-
ical examinations were included.23 The authors recommended that
future WHO guidelines exclude syndromic management of abnor-
mal vaginal discharge to detect cervical infection.23 Currently, the
WHO is in the process of revising its STI care guidelines.
Although antenatal syphilis testing is recommended by the
WHO and available in most countries, there continues to be chal-
lenges related to uptake. Globally, only a few countries have reached
at least 90% coverage during first antenatal care visits and in 26
countries, less than 50% of antenatal care attendees are tested for6 Sexuallsyphilis (data unavailable from the US).24 Further, in the US where
syphilis testing is a routine part of antenatal care, the number of con-
genital syphilis cases more than doubled between 2013 and 2017.25
Rates of Partner Notification and Treatment
Are Low
Partner notification is a process where sex partners of an in-
dex patient with an STI are identified, notified about their exposure,
counseled, and treated.26 Treating partners reduces the likelihood
of re-infecting the index patient,27 and decreases the burden of in-
fection in communities because the partners are often asymptom-
atic and otherwise unlikely to access care.28
Partner notification is governed by country-specific policies
related to the control of communicable diseases.29 There is variation
between countries; however, voluntary, patient-based partner notifi-
cation is the most common method globally.30 [31] Some countries
allow for expedited partner therapy, which is the clinical practice
of treating partners by providing medications to the index patient
to give to a partner prior to an examination of the partner by a
healthcare provider.[32] Regardless of the strategy, partner notifica-
tion is often low.[33, 34] A systematic review of partner notification
strategies in low- and middle-income countries found that the me-
dian proportion of sex partners notified in the 39 included studies
was 54%.[33] Limited prior research has found that although preg-
nant women report higher rates of willingness to notify partners
about an STI, this willingness does not always translate to higher
rates of partners receiving treatment.[33, 35]
Innovations May Allow for Improvements in STI
Testing, Treatment, and Prevention of Reinfection
Innovations in diagnostics may allow for the expansion of
STI testing and improved management, particularly in low resource
settings. Characteristics of new diagnostics include: easy to use,
multiplex, and patient-collected samples.[36] Additionally, STI diag-
nostic platforms are available that allow for patient diagnoses out-
side of clinical laboratories, have high sensitivity and specificity,
and allow for rapid results (while the patient is still present).[36]
Rapid tests have the potential to dramatically reduce the time be-
tween testing, results, and treatment, which may increase the like-
lihood of STI treatment and ultimately improve cure rates.[37]
Several studies have found that routine, rapid, antenatal syph-
ilis, CT, NG, and TV testing is acceptable, feasible, and cost-effective
in certain circumstances. A recent short report found that uptake of
antenatal STI testing was high across diverse settings ranging from
85.2% in the Democratic Republic of Congo to 99.3% in Vietnam.
Further, treatment was also high and ranged from 91.7% to 100%.[38]
In terms of cost-effectiveness, two recent studies evaluated
testing pregnant women for chlamydial infections.[39, 40] An Aus-
tralian study looked at antenatal CT testing amongwomen aged 16
to 25 years compared with women with no testing and found that
testing cost AU $183 more per case detected than no testing.[39] A
US-based study comparing testing all pregnant women to no test-
ing found that testing cost US $19 more per case detected and
treated.[40] Although both studies found that testing wasmore costly
than no testing, when considering adverse outcomes averted due to
testing and treatment (e.g., preterm birth and low birth weight in-
fants averted) testing resulted in cost savings at higher CT preva-
lence rates (e.g., Australia study threshold was 11% and US-study
was 16.9%). Those studies had several limitations that may change
the cost-effectiveness ratio: only short-term outcomes and costs
were assessed and benefits among partners were not examined.
Antenatal syphilis testing has been found to be cost effec-
tive even in low prevalence settings and cost-saving after adjusting
for avertedmedical care.[41] However, questions remain about howy Transmitted Diseases • Volume 47, Number 1, January 2020
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looked at the issue of whether to use point-of-care versus central-
ized testing and have different results depending on the setting. A
study inMongolia found that point-of-care testing reduced rates of
congenital syphilis compared with centralized testing.[42] How-
ever, a study in South Africa found that point-of-care testing did
not increase treatment rates, but reduced the time to treatment.[42]
A study in Zambia found that more women were tested using a
point-of-care strategy compared with centralized testing, but treatment
rates were not different.[43] In addition, utilizing dual point-of-care
testing for syphilis and HIV infection has the potential to simplify
training and procurement and reduce burdens on laboratories and
patients. Dual testing has been shown to be cost-effective.[44]
PATHOGENESIS OF ADVERSE MATERNAL,
PREGNANCY AND NEONATAL OUTCOMES
Mechanisms for Adverse Impact of Perinatal
Infectious on Pregnancy Outcomes
Sexually transmitted infections are associated with increased
inflammation,[45] which may play a role in adverse perinatal and in-
fant outcomes. Intrauterine infection/inflammation is associated
with about 40% of preterm deliveries.[46] An animal model where
intrauterine inflammation was induced by injection of agonists into
amniotic fluid,[47] found that the cytokine interleukin-1 (IL1) is a
critical mediator in perinatal inflammation. This result suggests
that IL1 is a potential therapeutic target. A cord blood study con-
ducted in Cincinnati found that intrauterine inflammation was as-
sociated with adverse pulmonary outcomes at 6 to 12 months in
moderate/late preterm infants.[48] Adverse outcomes associated
with low lung function at birth can continue well into the fourth
decade of life.[49, 50]
MYCOPLASMA GENITALIUM IN PREGNANCY
In women M. genitalium is common and associated with
adverse outcomes of pregnancy, including preterm birth, and is a
contributor to perinatal mortality and morbidity.[51, 52] A multisite
study in the United States of 1139 women at risk for STIs found
the prevalence of M. genitalium was 20.5%.[53] Another study in
the United States among pregnant women receiving routine ante-
natal care demonstrated a prevalence of 8.4%. Research is needed
to understand ifM. genitalium infects the placenta, chorion and/or
amnion, and/or causes inflammation and sequelae, such as neona-
tal conjunctivitis or respiratory distress. [51, 52]
Additional research is also needed to better understand the
impact and optimal regimen of M. genitalium treatment. Treat-
ments for M. genitalium have been hampered by antibiotic resis-
tance and some treatments, such as doxycycline, moxifloxacin, and
clarithromycin, are contraindicated or lack sufficient human data
in pregnancy. Azithromycin is a treatment option; however, resis-
tance is increasing and it is an FDA pregnancy category B drug.
Lefamulin may be a future treatment option as phase 2 clinical tri-
als of Lefamulin[54] have provided some safety data in pregnancy.
VAGINAL MICROBIOME AND PREGNANCY
Research of the human microbiome and its diversity has
helped to elucidate its role in health and human disease.[55] A nor-
mal vaginal microbiome is primarily dominated by Lactobacillus
species.[56] Lactobacillus species produce lactic acid to maintain
a normal vaginal pH and may play a role in preventing urogenital
diseases, such as bacterial vaginosis (BV), vaginal yeast infec-
tions, and urinary tract infections, as well as in acquiring or trans-
mitting STIs. Hence, disruption or modulation of the normal vaginalSexually Transmitted Diseases • Volume 47, Number 1, January 20microbiota may contribute to increased susceptibility to infectious
disease and adverse outcomes.
A study conducted by Ravel et al examined the vaginal
microbiome species composition of 396 asymptomatic, reproduc-
tive aged, North American women.[57] Investigators were able to
subdivide vaginal microbiomes into five community state types
(CST) including CST I: Lactobacillus crispatus, CST II: Lactoba-
cillus gasseri, CST III: Lactobacillus iners, CST IV: Lactobacillus
jensenii, and CST V: Lactobacillus-poor.[57] The proportion of
CST varied by race (i.e., white, black, Hispanic, and Asian) but
not by age. It was determined that L. crispatus was most associ-
ated with stable vaginal microbiota and that an abnormal vaginal
microbiome was associated with loss of lactic acid-producing
lactobacilli, higher Nugent scores (used in BV diagnosis; associated
with preterm birth), higher proportion ofGardnerella vaginalis, and
the presence of strict anaerobes.
A longitudinal analysis of the vaginal microbiome in preg-
nancy was conducted by collecting lateral vaginal wall swabs dur-
ing the first, second, and third trimester from 100 pregnant women
in Belgium.[58] From that study, 77 (77%) women were found to
have normal or Lactobacillus-dominated vaginal microflora dur-
ing the first trimester. Of these 77 women, 64 (83.1%) maintained
normal vaginal microbiota throughout their pregnancy, whereas
13 (16.9%) women converted to abnormal vaginal microbiota dur-
ing the second or third trimester. Women with L. gasseri and/or L.
iners were 10 times (RR = 9.49, 95% CI 1.30–69.40; P = 0.009)
more significantly likely to convert from normal to abnormal vag-
inal microbiota during pregnancy compared with women with
L. crispatus-dominated vaginal microbiota. Overall, it was con-
cluded that the species composition affects the stability of the vag-
inal microbiome in pregnancy.
Romero et al extended these findings by conducting a retro-
spective case-control longitudinal study of 22 healthy, pregnant
women (delivering at term) and 32 healthy, nonpregnant women
to characterize the vaginal microbiota during normal human preg-
nancy. They found that pregnant women had a higher abundance
of L. crispatus, L. gasseri, and L. jensenii and a lower abundance
of 22 other phylotypes (many associated with CST IV-A and IV-B)
over time compared with nonpregnant women.[59] In this study,
CST IV-B or CST IV-Awere characterized by a high relative abun-
dance of species of the genus Atopobium as well as Prevotella,
Sneathia, Gardnerella, Ruminococcaceae, Parvimonas,Mobiluncus,
and other taxa previously shown to be associated with BV. The au-
thors of this study hypothesized that maintaining a CST dominated
by Lactobacillus spp. during pregnancymay confer a protective role
against ascending infection of the genital tract during this time.
These same investigators subsequently conducted a nested
case-control study of pregnant women delivering at term (controls)
versus those with spontaneous preterm delivery before 34 weeks
of gestation (cases) to determine if any significant differences could
be found within the vaginal microbiome of women with preterm
versus term delivery.[60] Interestingly, the authors found no differ-
ence in the relative abundance of bacterial taxa in the vaginal
microbiome between women with spontaneous preterm delivery
and thosewho delivered at term. In addition, no differences in the fre-
quency of vaginal CSTs between women with spontaneous preterm
delivery and those who delivered at term. However, the results of this
study were limited by a small sample size (i.e., only 18 patients with
preterm delivery were included). In contrast, a prospective case-
control study [61] of 49 pregnant women by DiGiulio found that
prevalence of a Lactobacillus-poor vaginal community state type
(CST 4) with high levels of Gardnerella or Ureaplasma was in-
versely correlated with gestational age at delivery (P = 0.0039).
The study also found that most women experienced a postdelivery
disturbance in vaginal microbiota characterized by a decrease in20 7
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Peptoniphilus, Prevotella, and Anaerococcus spp. This disturbance
was unrelated togestational age at delivery andpersisted for up to 1year
after delivery. Reasons for the discordance between the results of this
study and that of Romeo et al[59] are likely multifactorial including dif-
ferences in the racial composition of the study cohorts, the timeframe
of pre-term birth cases, and whether or not pre-term birth was spon-
taneous or nonspontaneous.[61] Identifying signatures/markers in
the vaginal microbiota for predicting premature birth should be a
focus of future research efforts.
Hyman et al have also assessed the diversity of the vaginal
microbiome and its potential association with preterm birth in a
prospective study of 88 pregnant women.[62] L. crispatus was
found to be highly abundant in the vaginal microbiome of white
women, whereas L. iners was highly abundant in African
American and Hispanic women. Species diversity was greatest
among African American women. The investigators found that di-
versity of the vaginal microbiome correlated with preterm birth and
that race and ethnicity were important variables. Of the 19% of
women with preterm birth (among the 88 women followed), 15%
were Hispanic, 18% were white, 25% were African American,
and 25% were Asian.
Overall, studies conducted to-date have revealed that the vag-
inal microbiome becomes less diverse and more stable during
pregnancy and is largely dominated by Lactobacillus spp.[59]
Data collected thus far suggest that the distribution of predom-
inate vaginal CSTs during pregnancy varies by population,
race, and ethnicity. It is not clear, however, what precipitates
the shift from normal vaginal microbiota to abnormal vaginal
microbiota. Whether such shifts in CSTs are a result of (i) the
initial loss of vaginal lactobacilli, potentially caused by behav-
ioral activities or other inciting events, (ii) sexual acquisition of
a sexually transmitted pathogen that leads to complex changes
in the vaginal microbiota or (iii) sexual acquisition of a
polymicrobial consortium of microorganisms is not clear.[63]
Further, the influence of sexual activities on the vaginal micro-
biota during pregnancy is not well defined.VAGINAL MICROBIOME: NEXT STEPS
Much previous research related to the vaginal microbiome
are limited by small sample sizes, and thus more research is needed.
Further, research is needed to identify biomarkers associated
with adverse pregnancy outcomes in both uninfected women
and those infected with STIs. Future cohort or banked sample
studies will assess the species composition and regulation of the
vaginal microbiome during pregnancy, and will examine the se-
verity of STIs and pregnancy outcomes. Those studies are neces-
sary to define the relevant endpoints and clinical outcomes in
both pregnant and nonpregnant populations and examine variables
such as race and sexual behavior. However, the lack of standardi-
zation with regard to vaginal microbiome testing platforms is a
challenge that must first be addressed.[63, 64] From that work,
greater insight will be gained into STI etiology in pregnancy
and biomarkers/predictors of various outcomes including preterm
labor, membrane rupturing, still birth, early neonatal infections,
and immune modulation. A number of clinical studies of vaginal
probiotic supplementation with or without antimicrobials to im-
prove vaginal dysbiosis or pregnancy outcomes are either under-
way or planned (https://clinicaltrials.gov/ct2/results?cond=
&term=vaginal+probiotics&cntry=&state=&city=&dist=) how-
ever vaginal probiotics are not currently recommended for vaginal
dysbiosis in the CDC STD Treatment Guidelines.[65]8 SexuallGAPS AND CLINICAL ISSUES IN STI
PREVENTION/CONTROL
Gaps in Prevention and Control of
Congenital Syphilis
Congenital syphilis cases are on the rise in the United States,
and in 2017, there were 918 cases of congenital syphilis reported to
the CDC. To address the rise in syphilis among pregnant women,
as well as men who have sex with men, the CDC issued a call to
action[66] for communities impacted by congenital syphilis and
other groups who have a role to reduce the burden of infection
through research, treatment, and outreach. The CDC call to action
encourages key stakeholders to: Create new tools to detect and
treat syphilis and increase testing in order to control the further
spread of syphilis, and to improve electronicmedical records in or-
der to improve patient outcomes. In the call to action, the CDC
also published a list of stakeholders that they believe need to take
action. The CDCDivision of Sexually Transmitted Disease (STD)
Prevention (DSTDP) is undertaking a number of activities includ-
ing, ongoing epidemiological research and analysis of surveillance
data; convening local, state, and national partners to foster connec-
tivity and the promotion of best practices; developing and applying
care cascade and case review board practices to support in-depth
analysis of medical care gaps and congenital syphilis rates.
There are also state-level activities taking place. In 2017,
the CDC awarded nine state and local health department STD pro-
grams a total of US $4 million in order to enhance their congenital
syphilis responses. The goals of that program were to make sus-
tainable improvements to congenital syphilis related activities,
strengthen prevention through prospective information gathering
and interventions and retrospective activities to identify opportuni-
ties for change. Key activities included improving data collection
of maternal and fetal epidemiologic and clinical risk factors; im-
proved ascertainment of pregnancy status among female syphilis
cases; strengthening congenital syphilis morbidity and mortality
case review boards; matching syphilis surveillance data with vital
statistics; and strengthening partnerships with maternal and child
health programs and healthcare providers.
In addition to resources provided directly by the CDC,
funding is provided to support the National Network of STD Clin-
ical Prevention Training Centers (NNPTC) to assist clinicians in
the United States with the skills, knowledge, and experience that they
need to address and prevent STDs in their patients. The NNPTC
provides regional based in-person clinical training, as well as on-
line resources, including the STD clinical consultation network
(CCN (www.STDCCN.org)) and the national STD curriculum
that can be found at www.std.uw.edu. The curriculum includes
seven self-study modules with an individual progress tracker and
provides free continuing education credits.CLINICAL ISSUES RELATED TO STIs
AND PREGNANCY
Bacterial and viral STIs have an influence on pregnancy
outcomes and pregnancy can modify the manifestation of some
STIs. Thus, the timeliness of treatment during pregnancy is essen-
tial to avoid adverse outcomes.
Neonatal herpes simplex virus (HSV) infection occurs in
anywhere from 1 in 3,000 to 1 in 10,000 pregnancies.[67] An esti-
mated 1,500 cases of neonatal HSVoccur each year in the US and
more than 100 babies die from neonatal herpes.[67] Neonatal HSV
can be caused by either HSV-1 or HSV-2; however, two-thirds of
cases in the Americas are caused by HSV-1.[67] Worldwide neona-
tal HSV occurs in 10.3 per 100,000 live births and two-thirds ofy Transmitted Diseases • Volume 47, Number 1, January 2020
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HSV-2 has a seroprevalence between 20% and 30% and HSV-1
has a seroprevalence of 60%.[68] Approximately 10% ofHSV-2 se-
ronegative women have a seropositive partner, while up to one-
third of women of childbearing age are seronegative for HSV-1
and HSV-2 and 3.7% of those women will acquire either virus
during pregnancy.[68]
Eighty-five percent of babies who develop neonatal HSV
acquire the disease during labor and delivery.[69] Most transmis-
sions occur during asymptomatic shedding and most women have
no signs or symptoms. A study conducted on women giving birth
found that in recurrent HSV infection the risk of mother-to-child
transmission (MTCT) is quite low and that the risk of MTCT is
highest during the first episode of genital HSV.[69] Although most
benign forms of neonatal HSVoccur in the skin, eyes or mouth, 1
in 4 neonates will have a life-threatening disseminated infection.[70]
Incorporation of antiviral drugs during pregnancy, especially during
the third trimester, can reduce the clinical occurrence of maternal
HSV at the time of delivery by 75%.[71] Antiviral suppression can
also reduce the number of cesarean deliveries by 40% and can re-
duce viral shedding at the time of delivery by 90%.[71] There is in-
sufficient evidence about whether antiviral suppression late in the
third trimester can prevent neonatal herpes. Other strategies to re-
duce neonatal HSV include routine screening and better diagnos-
tic tools to confirm whether a suspicious legion is herpes. Rapid
point-of-care tests for HSV shedding would be helpful in reducing
cesarean deliveries and would allow neonatologists to implement
early antiretroviral therapy in infants born to mothers with HSV
shedding at the time of birth.
There are approximately 2 million cases of syphilis in preg-
nant women worldwide and syphilis is associated with adverse
pregnancy outcomes.6 Over the last 5 years, there has been an
87% increase in congenital syphilis worldwide.25 Timely treat-
ment is essential in preventing congenital syphilis, as over one half
of pregnancies in women with untreated syphilis will result in ad-
verse outcomes.[72] Implementation of point-of-care testing and/or
rapid tests are essential in order to detect syphilis earlier in pregnancy
and to reduce/prevent congenital syphilis worldwide.[73, 74] In
addition, standard of care treatment for pregnant women with
syphilis is the same as the standard of care treatment for non-
pregnant women. Penicillin is the recommended treatment to
prevent MTCT of syphilis and for treating neonatal infection.
Alternative treatments for syphilis can also be problematic; for
instance, there is limited data about the use of ceftriaxone in preg-
nant women to prevent congenital syphilis.[75] Additional barriers
to treatment of syphilis especially in pregnant women include pen-
icillin shortages and failure by insurers to cover fully penicillin for
syphilis treatment.[76] There are also concerns about the impact of
the opioid epidemic on syphilis and individuals who are unable or
unwilling to seek care.
Neisseria gonorrhoeae infections during pregnancy in-
crease the risk for preterm birth, premature rupture of membranes,
intraamniotic infection, low birth weight, and postpartum endometritis.
[77–79] Screening pregnant women who are at risk for NG infections
could help to reduceMTCTof both HIV infection and NG infection.17
Researching alternative treatments is also important as the only cur-
rently recommended regimen for NG in pregnancy is ceftriaxone
and azithromycin and there are limited options for alternative regi-
mens for patients with allergies or those with antibiotic resistance.19
Antenatal CT infection is also associated with preterm birth,
low birth weight, intrapartum fever, and late postpartum endometritis.
[80] Alternative treatment regimens are also urgently needed especially
for those with intolerance or allergies to current treatment regimens.
Trichomonas vaginalis infection is associated with vaginal
and systemic immune activation, as well as preterm delivery andSexually Transmitted Diseases • Volume 47, Number 1, January 20low birth weight.[81] However, questions remain about whether
at-risk pregnant women should be screened for TV infection. For
example, a previous study of screening and treating asymptomatic
TV during pregnancy did not reduce preterm delivery.[82]
In summary, because STIs in pregnancy may have serious
adverse consequences, timely diagnosis and treatment are important.
The data on some STIs in pregnancy are limited and dated. There is a
lack of data on comorbidities. Advances in diagnostics should be used
to optimize screening for, and treatment of STIs in pregnancy to pre-
vent maternal morbidity, adverse pregnancy outcome, and, trans-
mission to the neonate. Finally, effective anti-infective therapies
are needed to address issues such as antimicrobial resistance and
must be studied in pregnant women.[83]
GLOBAL ALLIANCE TO PREVENT PREMATURITY
AND STILLBIRTH BIOREPOSITORY
The mission of the Global Alliance to Prevent Prematurity
and Stillbirth (GAPPS) is to reduce the burden of preterm birth
and stillbirth by advancing collaborative research in order to identify,
develop, and implement evidence-based solutions.[84] The GAPPS
Biorepositorywas created in 2009 and opened in 2012 through phil-
anthropic support. The GAPPS Biorepository provides a unique
and widely accessible international biobank with comprehensive
maternal and newborn phenotypic data linked to high-quality tis-
sue biospecimens at several timepoints from early pregnancy
through childbirth and postpartum, which includes diverse popu-
lations and geographies. The GAPPS Biorepository model sup-
ports many types of research ranging from parturition to adverse
pregnancy outcomes including origins of chronic disease, genetics/
biology, pathophysiology, molecular etiology, epidemiology, diag-
nostics and biomarkers, translational science, health care delivery,
and new therapies/prevention solutions. Participants are enrolled
early in pregnancy with ultrasound dating of gestational age and
receive period follow-up during each trimester of pregnancy, and
at birth and during the postpartum period. Standardized clinical,
nutritional, and demographic data linked to biospecimens and
pregnancy case records with standardized classification of complica-
tions and adverse outcomes are collected. TheGAPPSBiorepository
provides state of the art systems for the collection, preservation,
managed access, and quality assurance of robust standardized data
for pregnancy and newborn cohorts that buildout and support a
global network of biorepositories in order to enable data sharing
and/or specimen transfer and accelerate research. In addition, efforts
continue to develop new, harmonized international repositories for
underrepresented populations. To date, the GAPPS Biorepository
has enrolled more than 4,500 women in Bangladesh, 3,000
women in the US and 1,500 women in Zambia.
The GAPPS Biorepository program is designed to be self-
sustainable, by addressing challenges to biobanking, including up-
front collection costs, regulatory burdens, participant retention,
supply chain, maintenance of technical equipment and data man-
agement, and anticipating needs to design relevant specimen/data
collections. The GAPPS Biorepository provides many collaborative
opportunities and a unique value proposition by improving effi-
ciencies, shortening research throughput, and reducing research
costs while providing the potential for follow up study of children
born to enrolled mothers and creating agnostic infrastructure for
future clinical trials and emerging multidiscipline research that ul-
timately benefit public health.
CLINICAL RESEARCH PRIORITIES
MOVING FORWARD
Three main clinical research priorities were identified (Table 1).
There is an urgent need to identify more STI treatments, especially for20 9
TABLE 1. Identified Clinical, Laboratory, and Policy Priorities to
Address STIs in Pregnancy
Clinical Research Priorities
1. Alternative treatments for STIs during pregnancy
2. Routine screening with point-of-care rapid diagnostic testing
for STIs during pregnancy globally
3. Further research into the vaginal microbiome
Laboratory Priorities
1. Assess STI test performance in pregnant vs. nonpregnant women
2. Develop further point-of-care tests
3. Develop microbial based biomarkers for adverse
pregnancy outcomes
4. Research in pathogenesis of intrauterine infection/inflammation
and the link between vaginal dysbiosis and intrauterine
infection/inflammation
Policy Priorities
1. Create Office of STI Research at the NIH.
2. Increase national policies that create and require monitoring
of standard antenatal care screening recommendations
and treatment practices
3. Include congenital syphilis in Infant Fetal and Infant
Mortality Reviews
4. Expand Federal funding for STD clinics to increase access
5. Increase STI screening and treatment in
PEPFAR-supported programs
6. Add STI screening and treatment as part of integrated antenatal
care packages globally
Wynn et al.pregnant women. A starting point is with studies of drugs that are
known to be safe and efficacious in nonpregnant adults. The use of
animal models and/or conducting retrospective trials in countries
where alternative therapies are used could provide useful prelimi-
nary data. Cord blood studies and ex vivo studies may serve as
possible avenues to improve the treatment of STIs in pregnancy.
Adequate infrastructure, personnel capacity, and cost-
effectiveness remain challenges to the implementation of routine
STI screening in pregnant women. Point-of-care rapid diagnostic
testing could provide solutions to some challenges, particularly in
low- and middle-income settings, because they are easy to use
and patients can collect their own samples. More evidence is needed
demonstrating the feasibility of application, scale-up, and cost-
effectiveness of STI screening during pregnancy, particularly stud-
ies that compare point-of-care versus off-site testing and multiple
versus single STI testing.
Finally, there is a need for greater understanding about the
relationship between the vaginal microbiome and STI transmis-
sion and acquisition.LABORATORY PRIORITIES
There are also four main laboratory priorities (Table 1). There
is an urgent need to develop novel point-of-care rapid diagnostic tests
that target pregnant women. Novel point-of-care rapid diagnostic tests
should be handheld, easy to operate, cost effective, and should return
results quickly so that patients may be quickly treated. Development
of such novel point-of-care tests could help reduce transmission of
STIs and be used as a triage tool or confirmatory device to help
reduce overtreatment. To reduce costs, improve the ability to de-
tect and treat comorbidities, and improve maternal and perinatal
outcomes, new STI tests should be designed to be able to detect
multiple pathogens.
Studies have shown some promise related to the use of the
vaginal microbiome as a predictor of pregnancy outcomes; how-
ever, markers have shown a very small impact in terms of public
health. Larger studies are needed to validate before testing10 Sexuallstudies are implemented. Further, it is necessary to move from
exploratory studies toward longitudinal studies. Finally, more
research is needed in to the pathogenesis of intrauterine
infection/inflammation and how vaginal dysbiosis can cause
intrauterine infection/inflammation.POLICY PRIORITIES
In the US, the creation of an Office of STI Research at the
National Institutes of Health (NIH) would allow for better integra-
tion of STI research policies and priorities, especially as relevant to
HIV research while working in conjunction with the Office of
AIDS Research. Policies should be implemented that create and
require the monitoring of standard antenatal care screening recom-
mendations and treatment practices across the US. Given the re-
cent upsurge in STIs in the US, funding increases for the CDC's
STD prevention efforts and the Centers of Excellence in STI Treat-
ment are needed. In the context of a congenital syphilis crisis, it
would be useful to expand the Fetal and Infant Mortality Review
to include congenital syphilis. Utilizing federal funding to expand
the number and hours of local STD clinics could better serve com-
munities at risk. Highlighting jurisdictions that are doing well with
STI screening and treatment, especially during pregnancy, could
incentivize improvements in care. Furthermore, PEPFAR supported
initiatives should increase STI screening, testing and care programs,
and at least 20% of funding from PEPFAR and the Global Fund
should be focused on STIs.
Routine STI screening during pregnancy should be in-
cluded in the WHO guidelines. The WHO recently published an-
tenatal care guidelines that include HIV, syphilis, urinary tract
infection, malaria, and anemia screening, depending on the geo-
graphic location.[85] If enough evidence is not available to do so,
the WHO should convene a meeting including relevant experts
to identify research gaps and plan a program to address those gaps.
Providers and researchers also need to continue to request an inte-
grated approach to antenatal and postnatal care inclusive of STI
screening and treatment in policy and practice.REFERENCES
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